Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (4)

Search Parameters:
Keywords = Poon Chung-kwong

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
11 pages, 276 KiB  
Article
Poon Chung-kwong’s (b. 1940) Apologetic Discourse Towards the Compatibility Between Pure Land Buddhism and Natural Science
by Saiping An
Religions 2025, 16(2), 175; https://doi.org/10.3390/rel16020175 - 4 Feb 2025
Viewed by 1242
Abstract
This study delves into the apologetic discourse put forward by Poon Chung-kwong 潘宗光 (b. 1940), who is both a scientist and a lay Buddhist of contemporary Hong Kong, concerning the compatibility of Pure Land Buddhism and natural science. It centers on an analysis [...] Read more.
This study delves into the apologetic discourse put forward by Poon Chung-kwong 潘宗光 (b. 1940), who is both a scientist and a lay Buddhist of contemporary Hong Kong, concerning the compatibility of Pure Land Buddhism and natural science. It centers on an analysis of his application of diverse physical knowledge to elucidate the description of Sukhāvatī, an ideal and enigmatic world, within Buddhist texts. Poon endeavors to demonstrate that multiple facets of Sukhāvatī, including its establishment and the rebirth of believers within this domain, are congruent with scientific principles. This is in an effort to counter the public’s perception of Buddhism as “unscientific” or even “superstitious”, notwithstanding that some physical theories he employed are still in the inferential stage and, furthermore, are enmeshed in controversy, which substantially undermines the cogency of his apologetic discourses. This study presents a case of the interaction between Pure Land Buddhism and natural science, which has hitherto been overlooked by the academic community. Full article
(This article belongs to the Special Issue Images of the World in the Dialogue between Science and Religion)
14 pages, 912 KiB  
Article
Expanded Newborn Screening for Inborn Errors of Metabolism in Hong Kong: Results and Outcome of a 7 Year Journey
by Kiran Moti Belaramani, Toby Chun Hei Chan, Edgar Wai Lok Hau, Matthew Chun Wing Yeung, Anne Mei Kwun Kwok, Ivan Fai Man Lo, Terry Hiu Fung Law, Helen Wu, Sheila Suet Na Wong, Shirley Wai Lam, Gladys Ha Yin Ha, Toby Pui Yee Lau, Tsz Ki Wong, Venus Wai Ching Or, Rosanna Ming Sum Wong, Wong Lap Ming, Jasmine Chi Kwan Chow, Eric Kin Cheong Yau, Antony Fu, Josephine Shuk Ching Chong, Ho Chung Yau, Grace Wing Kit Poon, Kwok Leung Ng, Kwong Tat Chan, Yuen Yu Lam, Joannie Hui, Chloe Miu Mak and Cheuk Wing Fungadd Show full author list remove Hide full author list
Int. J. Neonatal Screen. 2024, 10(1), 23; https://doi.org/10.3390/ijns10010023 - 11 Mar 2024
Cited by 5 | Viewed by 3558
Abstract
Newborn screening (NBS) is an important public health program that aims to identify pre-symptomatic healthy babies that will develop significant disease if left undiagnosed and untreated. The number of conditions being screened globally is expanding rapidly in parallel with advances in technology, diagnosis, [...] Read more.
Newborn screening (NBS) is an important public health program that aims to identify pre-symptomatic healthy babies that will develop significant disease if left undiagnosed and untreated. The number of conditions being screened globally is expanding rapidly in parallel with advances in technology, diagnosis, and treatment availability for these conditions. In Hong Kong, NBS for inborn errors of metabolism (NBSIEM) began as a pilot program in October 2015 and was implemented to all birthing hospitals within the public healthcare system in phases, with completion in October 2020. The number of conditions screened for increased from 21 to 24 in April 2016 and then to 26 in October 2019. The overall recruitment rate of the NBS program was 99.5%. In the period between October 2015 and December 2022, 125,688 newborns were screened and 295 were referred back for abnormal results. The recall rate was reduced from 0.26% to 0.12% after the implementation of second-tier testing. An inherited metabolic disorder (IMD) was eventually confirmed in 47 infants, making the prevalence of IMD in Hong Kong 1 in 2674. At the time of the NBS result, 78.7% of the newborns with IMD were asymptomatic. There were two deaths reported: one newborn with methylmalonic acidemia cobalamin B type (MMACblB) died after the initial crisis and another case of carnitine palmitoyltransferase II deficiency (CPTII) died at 18 months of age after metabolic decompensation. The most common IMD noted were disorders of fatty acid oxidation metabolism (40%, 19 cases), closely followed by disorders of amino acid metabolism (38%, 18 cases), with carnitine uptake defect (19.1%, 9 cases) and citrullinemia type II (17%, 8 cases) being the two most common IMD picked up by the NBSIEM in Hong Kong. Out of the all the IMDs identified, 19.1% belonged to diverse ethnic groups. False negative cases were reported for citrullinemia type II and congenital adrenal hyperplasia during this period. Full article
Show Figures

Figure 1

14 pages, 2853 KiB  
Article
Characterization of the Gut Microbiome in Healthy Dogs and Dogs with Diabetes Mellitus
by Tsz Ching Kwong, Eddie Chung Ting Chau, Mark Chi Ho Mak, Chi Tung Choy, Lee Tung Chan, Chun Keung Pang, Junwei Zhou, Phoebe Hoi Ching Poon, Yuqiong Guan, Stephen Kwok Wing Tsui, Shun Wan Chan, George Pak Heng Leung, William Chi Shing Tai and Yiu Wa Kwan
Animals 2023, 13(15), 2479; https://doi.org/10.3390/ani13152479 - 1 Aug 2023
Cited by 9 | Viewed by 3346
Abstract
With a close pathogenetic resemblance to human diabetes, canine Diabetes Mellitus, a chronic metabolic disease featuring abnormally high blood sugar levels, is increasing in prevalence worldwide. Unlike humans, canine glycemic control requires life-long insulin injections and dietary control in most cases, thereby jeopardizing [...] Read more.
With a close pathogenetic resemblance to human diabetes, canine Diabetes Mellitus, a chronic metabolic disease featuring abnormally high blood sugar levels, is increasing in prevalence worldwide. Unlike humans, canine glycemic control requires life-long insulin injections and dietary control in most cases, thereby jeopardizing diabetic dogs’ quality of life and increasing the difficulty of disease control. While many research studies have focused on elucidating the relationship between the canine gut microbiome and diseases, there is currently no research on the subject of diabetes mellitus in dogs. We hypothesized that the gut microbiome of canines with diabetes mellitus is different from that of healthy controls. Thus, we performed targeted 16S rRNA sequencing and comprehensive bioinformatic analysis to compare the gut microbiome profiles of 16 diabetic dogs with those of 32 healthy dogs. Clostridioides difficile, Phocaeicola plebeius, Lacrimispora indolis, and Butyricicoccus pullicaecorum were found to be enriched in diabetic dogs. A distinct shift towards carbohydrate degradation metabolic pathways was found to be differentially abundant in the diabetic subjects. Alteration of the co-occurrence network was also evident in the diabetic group. In conclusion, our study suggests that the gut microbial landscape differs in diabetic canines at the genera, species, functional, and network levels. These findings have significant implications for disease management, and thus warrant further research. Full article
(This article belongs to the Special Issue Microbial Genomics in Animal Sciences)
Show Figures

Figure 1

13 pages, 943 KiB  
Review
Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer
by Darren M. C. Poon, Kuen Chan, Tim Chan, Foo-Yiu Cheung, Daisy Lam, Martin Lam, Ka-Suet Law, Conrad Lee, Eric K. C. Lee, Angus Leung, Henry Sze, Chi-Chung Tong, Kenneth C. W. Wong and Philip Kwong
Cancers 2022, 14(2), 407; https://doi.org/10.3390/cancers14020407 - 14 Jan 2022
Cited by 7 | Viewed by 3447
Abstract
Progression to metastatic disease occurs in about half of all men who develop prostate cancer (PC), one of the most common cancers in men worldwide. Androgen deprivation therapy has been the mainstay therapy for patients with metastatic PC (mPC) since the 1940s. In [...] Read more.
Progression to metastatic disease occurs in about half of all men who develop prostate cancer (PC), one of the most common cancers in men worldwide. Androgen deprivation therapy has been the mainstay therapy for patients with metastatic PC (mPC) since the 1940s. In the last decade, there has been unprecedented advancement in systemic therapies, e.g., taxane, androgen-signalling pathway inhibitors, and biomarker-driven targeted therapies for various stages of disease, resulting in overall survival improvement. Adding to ongoing controversies over how best to treat these patients is the recognition that ethnicity may influence prognosis and outcomes. This review discusses recent evidence for the impacts of Asian ethnicity specifically, which includes environmental, sociocultural, and genetic factors, on the approach to pharmacological management of mPC. Clear inter-ethnic differences in drug tolerability, serious adverse events (AEs), and genetic heterogeneity must all be considered when dosing and scheduling for treatment, as well as designing future precision studies in PC. Full article
(This article belongs to the Special Issue Advanced Prostate Cancer: From Bench to Bedside)
Show Figures

Graphical abstract

Back to TopTop